Triphase Receives FDA Orphan Drug Designation For Marizomib In Multiple Myeloma

TORONTO & SAN DIEGO--(BUSINESS WIRE)--Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA)'s Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

Help employers find you! Check out all the jobs and post your resume.